Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis
- PMID: 2223581
- PMCID: PMC1971477
- DOI: 10.1038/bjc.1990.345
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis
Abstract
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
Similar articles
-
Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.Int J Cancer. 1992 Aug 19;52(1):38-43. doi: 10.1002/ijc.2910520109. Int J Cancer. 1992. PMID: 1500225
-
Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates.Recent Results Cancer Res. 1996;141:145-58. doi: 10.1007/978-3-642-79952-5_10. Recent Results Cancer Res. 1996. PMID: 8722425 Clinical Trial. No abstract available.
-
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.J Neurooncol. 1995;24(1):109-22. doi: 10.1007/BF01052668. J Neurooncol. 1995. PMID: 8523067 Clinical Trial.
-
Progress review: intrathecal and intratumoral injection of radiolabelled monoclonal antibodies (MoAbs) for the treatment of central nervous system (CNS) malignancies.J Drug Target. 1993;1(3):175-83. doi: 10.3109/10611869308996074. J Drug Target. 1993. PMID: 8069558 Review.
-
Neoplastic meningitis: diagnosis and treatment considerations.Med Oncol. 2000 Aug;17(3):151-62. doi: 10.1007/BF02780522. Med Oncol. 2000. PMID: 10962524 Review.
Cited by
-
Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?Eur J Nucl Med. 1992;19(3):205-13. doi: 10.1007/BF00173283. Eur J Nucl Med. 1992. PMID: 1572386 Review.
-
Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review.J R Soc Med. 1993 Apr;86(4):219-24. doi: 10.1177/014107689308600413. J R Soc Med. 1993. PMID: 8505732 Free PMC article. Review. No abstract available.
-
Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.J Neurooncol. 1997 Dec;35(3):259-73. doi: 10.1023/a:1005812417638. J Neurooncol. 1997. PMID: 9440024 Review. No abstract available.
-
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.Surg Neurol Int. 2013 May 2;4(Suppl 4):S265-88. doi: 10.4103/2152-7806.111304. Print 2013. Surg Neurol Int. 2013. PMID: 23717798 Free PMC article.
-
Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.Br J Cancer. 1998 Jun;77(12):2324-30. doi: 10.1038/bjc.1998.386. Br J Cancer. 1998. PMID: 9649153 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical